MarginsXMarginsX
Home › Markets › Health Care › ANL

Adlai Nortye Group Ltd. (ANL)

ANL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.03
-5.47% on the day
Market cap
$645.9M
Small cap
Revenue · 2025
$5.0M
Prior year not contiguous
Net income · 2025
-$35.5M
-710.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1944552/000121390026042520/0001213900-26-042520-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerANL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCayman Islands
IPO year2023
SEC CIK0001944552
SEC industry codePharmaceutical Preparations
Incorporated inSingapore

Financials · 2025

LineValue
Revenue$5.0M
Net income-$35.5M
Operating income-$35.7M
Net margin-710.6%
Operating margin-714.0%
Revenue growthNo prior-year revenue to compare
Cash$8.1M
Total assets$34.4M
P/E (computed)Net income was not positive
P/S (computed)129.2×

Warning signs

Cash runway
2.9 months
$8.1M cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed April 10, 2026
Insider net buying, 12 months
-$248K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-10
Cash and burn$8.1M cash; operating cash flow -$8.4M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-03-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorMazars USA LLP, New York, New York, United StatesPCAOB Form AP 2024-04-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $248K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$5.0M-$35.5M-$33.5M$8.1M$24.6M$5.0M20-F 2026-04-10
FY 2024
2024-12-31
Not filed-$51.9M-$51.8M$60.9M$26.3MNeeds four quarters20-F/A 2025-05-12
FY 2023
2023-12-31
$5.0M-$109.2M-$56.7M$91.5M$30.4M$5.0M20-F/A 2025-05-12
FY 2022
2022-12-31
Not filed-$58.8M-$43.2M$42.8M$4.3MNeeds four quarters20-F/A 2025-05-12
FY 2021
2021-12-31
$45.7M-$56.7M-$3.0M$64.1M$10.5M$45.7M20-F/A 2025-02-14

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3
POS AM2026-09-11
Latest annual report
ANNUAL REPORT
20-F2026-04-10
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-10-28

Source: SEC EDGAR submissions feed, 114 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.2%
1 month-9.7%
3 months-17.5%
Year to date+647.2%
1 year+602.6%
From 52-week high-36.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OLMAOlema Oncology Inc.$7.36-2.65%$644.8M
BCAXBicara Therapeutics Inc.$9.75-2.69%$647.3M
KURAKura Oncology Inc.$7.09-8.75%$651.4M
DSGNDesign Therapeutics Inc.$9.92-5.25%$635.2M
NVCTNuvectis Pharma Inc.$19.11-5.58%$657.2M
IMMXImmix Biopharma Inc.$7.48-4.59%$626.9M
ALMSAlumis Inc.$5.14-8.21%$667.3M
JANXJanux Therapeutics Inc.$10.92-3.96%$668.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier